TherapeuticsMD Files 8-K on Shareholder Vote Matters
Ticker: TXMD · Form: 8-K · Filed: Dec 16, 2025 · CIK: 25743
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: TXMD
TL;DR
TXMD is asking shareholders to vote on stuff. Keep an eye on the outcome.
AI Summary
On December 15, 2025, TherapeuticsMD, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing indicates that the company is seeking approval on certain proposals from its shareholders.
Why It Matters
This filing signals that TherapeuticsMD is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural, reporting on a shareholder vote, and does not contain new financial or operational risks.
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- December 15, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of Incorporation
- Boca Raton, FL (location) — Business Address
FAQ
What specific matters are being submitted for a vote of security holders?
The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals within this 8-K filing itself. Further details would typically be found in related proxy materials.
When was the earliest event reported in this filing?
The earliest event reported was on December 15, 2025.
What is the exact name of the registrant?
The exact name of the registrant is TherapeuticsMD, Inc.
In which state is TherapeuticsMD, Inc. incorporated?
TherapeuticsMD, Inc. is incorporated in Nevada.
What is the company's primary business address?
The company's business address is 951 Yamato Road, Suite 220, Boca Raton, FL.
Filing Stats: 988 words · 4 min read · ~3 pages · Grade level 15.7 · Accepted 2025-12-16 16:01:06
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Mar
Filing Documents
- ea0269797-8k_therap.htm (8-K) — 52KB
- 0001213900-25-122240.txt ( ) — 215KB
- txmd-20251215.xsd (EX-101.SCH) — 3KB
- txmd-20251215_lab.xml (EX-101.LAB) — 33KB
- txmd-20251215_pre.xml (EX-101.PRE) — 22KB
- ea0269797-8k_therap_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 16, 2025 THERAPEUTICSMD, INC. /s/ Marlan Walker Marlan Walker Chief Executive Officer 2